• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

锥体外系症状是抗精神病药物和其他药物的严重副作用。

Extrapyramidal symptoms are serious side-effects of antipsychotic and other drugs.

作者信息

Blair D T, Dauner A

机构信息

Colmery-O'Neil Veterans Administration Medical Center, Topeka, Kan.

出版信息

Nurse Pract. 1992 Nov;17(11):56, 62-4, 67. doi: 10.1097/00006205-199211000-00018.

DOI:10.1097/00006205-199211000-00018
PMID:1359485
Abstract

Antipsychotic medications commonly produce extrapyramidal symptoms as side effects. The extrapyramidal symptoms include acute dyskinesias and dystonic reactions, tardive dyskinesia, Parkinsonism, akinesia, akathisia, and neuroleptic malignant syndrome. Extrapyramidal symptoms are caused by dopamine blockade or depletion in the basal ganglia; this lack of dopamine often mimics idiopathic pathologies of the extrapyramidal system. Less recognized is that extrapyramidal symptoms are also associated with certain non-antipsychotic agents, including some antidepressants, lithium, various anticonvulsants, antiemetics and, rarely, oral-contraceptive agents. Extrapyramidal symptoms caused by these agents are indistinguishable from neuroleptic-induced extrapyramidal symptoms. Clinicians must be able to recognize these side effects and be able to determine the antipsychotic-induced and non-antipsychotic causes of extrapyramidal symptoms.

摘要

抗精神病药物通常会产生锥体外系症状作为副作用。锥体外系症状包括急性运动障碍和张力障碍反应、迟发性运动障碍、帕金森症、运动不能、静坐不能以及抗精神病药恶性综合征。锥体外系症状是由基底神经节中的多巴胺阻断或耗竭引起的;这种多巴胺缺乏常常模仿锥体外系的特发性病变。较少被认识到的是,锥体外系症状也与某些非抗精神病药物有关,包括一些抗抑郁药、锂盐、各种抗惊厥药、止吐药,以及很少见的口服避孕药。这些药物引起的锥体外系症状与抗精神病药引起的锥体外系症状无法区分。临床医生必须能够识别这些副作用,并能够确定锥体外系症状的抗精神病药诱导原因和非抗精神病药原因。

相似文献

1
Extrapyramidal symptoms are serious side-effects of antipsychotic and other drugs.锥体外系症状是抗精神病药物和其他药物的严重副作用。
Nurse Pract. 1992 Nov;17(11):56, 62-4, 67. doi: 10.1097/00006205-199211000-00018.
2
Nonneuroleptic etiologies of extrapyramidal symptoms.锥体外系症状的非抗精神病药物病因
Clin Nurse Spec. 1993 Jul;7(4):225-31. doi: 10.1097/00002800-199307000-00018.
3
The pathophysiology of extrapyramidal side-effects of neuroleptic drugs.抗精神病药物锥体外系副作用的病理生理学
Psychol Med. 1980 Feb;10(1):55-72. doi: 10.1017/s003329170003960x.
4
Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.氯氮平治疗精神分裂症患者的抗精神病药物所致迟发性运动障碍、帕金森症及慢性静坐不能。
J Clin Psychiatry. 1997 Jul;58(7):318-22. doi: 10.4088/jcp.v58n0706.
5
[Drug induced movement disorders: role of antipsychotic drugs].
Acta Med Port. 2011 Dec;24 Suppl 4:915-22. Epub 2011 Dec 31.
6
Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia.
Psychiatr Clin North Am. 1993 Sep;16(3):589-610.
7
Neuroleptic side effects: acute extrapyramidal syndromes and tardive dyskinesia.
Psychopharmacol Ser. 1988;5:74-93. doi: 10.1007/978-3-642-73280-5_7.
8
Drug-Induced Extrapyramidal Syndromes: Implications for Contemporary Practice.药物性锥体外系综合征:对当代临床实践的影响
Psychiatr Clin North Am. 2016 Sep;39(3):391-411. doi: 10.1016/j.psc.2016.04.003. Epub 2016 Jun 23.
9
[Neuroleptic-induced movement disorders: historical perspectives].[抗精神病药物所致运动障碍:历史视角]
Encephale. 1993 Nov-Dec;19(6):657-61.
10
Side effects in preventive maintenance therapy with neuroleptics with special emphasis on tardive dyskinesia.抗精神病药预防性维持治疗中的副作用,特别强调迟发性运动障碍。
Bibl Psychiatr. 1981(160):22-9. doi: 10.1159/000392252.

引用本文的文献

1
Exploring the Relationships Between Antipsychotic Dosage and Voice Characteristics in Relation to Extrapyramidal Symptoms.探究抗精神病药物剂量与语音特征之间与锥体外系症状相关的关系。
Psychiatry Investig. 2024 Aug;21(8):822-831. doi: 10.30773/pi.2023.0417. Epub 2024 Aug 8.
2
Levofloxacin-Induced Oromandibular Dystonia in a 9-Year-Old Patient.一名9岁患者因左氧氟沙星诱发口下颌肌张力障碍
Iran J Child Neurol. 2024 Summer;18(3):151-157. doi: 10.22037/ijcn.v18i3.18054. Epub 2024 Jun 22.
3
MolScore: a scoring, evaluation and benchmarking framework for generative models in de novo drug design.
MolScore:一种用于从头药物设计中生成模型的评分、评估和基准测试框架。
J Cheminform. 2024 May 30;16(1):64. doi: 10.1186/s13321-024-00861-w.
4
Understanding neuropsychiatric symptoms in Alzheimer's disease: challenges and advances in diagnosis and treatment.了解阿尔茨海默病中的神经精神症状:诊断与治疗的挑战和进展
Front Neurosci. 2023 Sep 5;17:1263771. doi: 10.3389/fnins.2023.1263771. eCollection 2023.
5
The antipsychotic medications aripiprazole, brexpiprazole and cariprazine are off-target respiratory chain complex I inhibitors.抗精神病药物阿立哌唑、布瑞哌唑和卡利哌嗪是非靶标呼吸链复合物 I 抑制剂。
Biol Direct. 2023 Aug 1;18(1):43. doi: 10.1186/s13062-023-00375-9.
6
Novel Multimodal Salicylamide Derivative with Antidepressant-like, Anxiolytic-like, Antipsychotic-like, and Anti-Amnesic Activity in Mice.新型多模式水杨酰胺衍生物在小鼠中具有抗抑郁样、抗焦虑样、抗精神病样和抗失忆活性
Pharmaceuticals (Basel). 2023 Jan 24;16(2):175. doi: 10.3390/ph16020175.
7
Risk factors, clinical correlates, and social functions of Chinese schizophrenia patients with drug-induced parkinsonism: A cross-sectional analysis of a multicenter, observational, real-world, prospective cohort study.中国药物性帕金森综合征型精神分裂症患者的危险因素、临床关联及社会功能:一项多中心、观察性、真实世界、前瞻性队列研究的横断面分析
Front Pharmacol. 2023 Mar 3;14:1077607. doi: 10.3389/fphar.2023.1077607. eCollection 2023.
8
3,4-Methylenedioxypyrovalerone High-Responder Phenotype as a Tool to Evaluate Candidate Medications for Stimulant Use Disorder.3,4-亚甲二氧基吡咯戊酮高反应表型可作为评估治疗兴奋剂使用障碍候选药物的工具。
J Pharmacol Exp Ther. 2023 Mar;384(3):353-362. doi: 10.1124/jpet.122.001419. Epub 2023 Jan 10.
9
Adding pre-emptive anticholinergics to antipsychotics: Is it justified?在抗精神病药物中添加预防性抗胆碱能药物:是否合理?
Ind Psychiatry J. 2022 Jul-Dec;31(2):370-373. doi: 10.4103/ipj.ipj_269_21. Epub 2022 Aug 30.
10
Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders.靶向毒蕈碱受体的药物设计及其对中枢神经系统疾病的影响
Biomedicines. 2022 Feb 7;10(2):398. doi: 10.3390/biomedicines10020398.